Session 059: ACA Risk Adjustment Data Validation – It Matters! Learning from Year 1 and BeyondSession 059: ACA Risk Adjustment Data Validation – It Matters! Learning from Year ... closely follow federal law. The Sherman Act, is the primary U.S. antitrust law pertaining to association activities ...
Description: "The ACA RADV Program will begin to impact issuers’ risk transfers in the 2018 benefit year (BY) – potentially significantly. The program is expected to continue into the 2019 BY and beyond. Therefore, health actuaries working in the ACA market need to understand this program and its potential impact.The session includes panel experts who will provide attendees with high-level overview of the program, discuss the findings from a national study, and RADV’s ultimate impact to risk transfers, as well as downstream impacts to financial and pricing decisions. The nationwide study is based on 300+ issuers’ 2016 RADV results and contains emerging insights into the new ACA RADV program otherwise unavailable. The panel’s agenda will include:1. A succinct overview of the ACA RADV Program will be provided2. Summary of a national 2016 ACA RADV pilot study results and its findings. 3. Preliminary results from a national 2017 RADV study will be discussed (or CMS published results if available prior to session). 4. Walkthrough of how RADV results impact the overall risk adjustment transfers in the ACA market. 5. Finally, the panel will discuss RADV impact to issuer’s financial accruals and pricing strategy. 6. General Q&A, discussion"Hide
- Authors: Karena Weikel, Chia Yi Chin, Matthew Sauter, Alexander Mark Vojta
- Date: Jul 2019
- Competency: Strategic Insight and Integration
- Topics: Health & Disability>Health insurance